Sign inCreate account

Report workspace tools

NCT01722669COMPLETEDanonymous

Pharmacokinetic and Pharmacodynamic Study of Oral Quercetin and Isoquercetin in Healthy Adults and Patients With Hypercoagulable States.

Sponsor

Source record

Beth Israel Deaconess Medical Center

Phase

Source record

Early Phase 1

Modality

AI-normalized

small molecule

Target

AI-normalized

Quercetin and Isoquercetin pharmacokinetics and pharmacodynamics

Indication / condition

AI-normalized

Healthy

Intervention

Source record

isoquercetin or quercetin

Source & freshness

Source record

NCT ID

NCT01722669

Original source

ClinicalTrials.gov

Source last updated

Oct 12, 2020

Ingested at

May 30, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT01722669

Title

Pharmacokinetic and Pharmacodynamic Study of Oral Quercetin and Isoquercetin in Healthy Adults and Patients With Hypercoagulable States.

Sponsor

Beth Israel Deaconess Medical Center

Status

COMPLETED

Phase

Early Phase 1

Condition raw

Healthy

Condition normalized

Healthy

Modality raw

Healthy

Modality normalized

small molecule

Target raw

Quercetin and Isoquercetin pharmacokinetics and pharmacodynamics

Target normalized

Quercetin and Isoquercetin pharmacokinetics and pharmacodynamics

Interventions

isoquercetin or quercetin

Public preview

Source record

This study evaluated the absorption and activity of quercetin and isoquercetin in healthy adults and patients with hypercoagulable states. The trial was conducted by Beth Israel Deaconess Medical Center and involved 38 participants across various arms, assessing pharmacokinetic parameters and pharmacodynamic effects.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Pharmacokinetic and Pharmacodynamic Study of Oral Quercetin and Isoquercetin in Healthy Adults and Patients With Hypercoagulable States.

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT01722669

Status

COMPLETED

Phase

Early Phase 1

Sponsor

Beth Israel Deaconess Medical Center

Executive brief

Investment-Ready Snapshot

This study evaluated the absorption and activity of quercetin and isoquercetin in healthy adults and patients with hypercoagulable states. The trial was conducted by Beth Israel Deaconess Medical Center and involved 38 participants across various arms, assessing pharmacokinetic parameters and pharmacodynamic effects.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedOct 12, 2020
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT01722669

Indication

Healthy

Modality

small molecule

Target

Quercetin and Isoquercetin pharmacokinetics and pharmacodynamics

Intervention

isoquercetin or quercetin

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.